{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.42","upperLimit":"0.73","value":"0.58"},{"groupId":"OG001","lowerLimit":"0.61","upperLimit":"0.89","value":"0.77"},{"groupId":"OG002","lowerLimit":"0.42","upperLimit":"0.79","value":"0.62"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"21"}],"units":"Participants"}],"description":"Proportion of patients alive and disease-free 18 months from autologous stem cell transplantation (ASCT). Progression criteria are per Lugano 2014 criteria. All patients receiving any amount of protocol treatment. Patients who have progressed or lost to follow-up prior to 18 months are counted as failures; only patients followed and progression-free for at least 18 months are counted as successes.","dispersionType":"90% Confidence Interval","groups":[{"description":"Pembrolizumab 200mg IV every 3 weeks up to 8 cycles\n\nPembrolizumab: Anti-PD-1 monoclonal antibody","id":"OG000","title":"Diffuse Large B Cell Lymphoma"},{"description":"Pembrolizumab 200mg IV every 3 weeks up to 8 cycles\n\nPembrolizumab: Anti-PD-1 monoclonal antibody","id":"OG001","title":"Classical Hodgkin Lymphoma"},{"description":"Pembrolizumab 200mg IV every 3 weeks up to 8 cycles\n\nPembrolizumab: Anti-PD-1 monoclonal antibody","id":"OG002","title":"Peripheral T Cell Lymphoma"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"18 Months","title":"Progression-free Survival After ASCT","type":"PRIMARY","unitOfMeasure":"proportion of participants"}